Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0941 and Cisplatin in AR-Negative Triple-Negative Metastatic Breast Cancer
NCT01918306Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Sep 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pictilisib in triple-negative breast cancer (TNBC), sponsored by Vanderbilt-Ingram Cancer Center. Started Sep 2013; status: terminated.
02
Drugs
pictilisib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01918306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01918306.